DaVita Inc. $DVA Shares Sold by Berkshire Hathaway Inc

Berkshire Hathaway Inc trimmed its position in shares of DaVita Inc. (NYSE:DVA) by 1.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 31,759,065 shares of the company’s stock after selling 401,514 shares during the quarter. DaVita accounts for approximately 1.3% of Berkshire Hathaway Inc’s portfolio, making the stock its 11th largest holding. Berkshire Hathaway Inc owned about 0.48% of DaVita worth $3,608,147,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in DVA. Arrowstreet Capital Limited Partnership increased its stake in shares of DaVita by 114.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock worth $135,196,000 after acquiring an additional 636,191 shares during the period. Norges Bank acquired a new position in shares of DaVita during the fourth quarter worth about $49,164,000. Man Group plc increased its stake in shares of DaVita by 1,608.6% during the second quarter. Man Group plc now owns 285,809 shares of the company’s stock worth $40,713,000 after acquiring an additional 269,081 shares during the period. Neuberger Berman Group LLC increased its stake in shares of DaVita by 138.5% during the third quarter. Neuberger Berman Group LLC now owns 463,250 shares of the company’s stock worth $61,502,000 after acquiring an additional 269,015 shares during the period. Finally, Voloridge Investment Management LLC increased its stake in shares of DaVita by 2,905.7% during the third quarter. Voloridge Investment Management LLC now owns 228,221 shares of the company’s stock worth $30,324,000 after acquiring an additional 220,628 shares during the period. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the transaction, the insider owned 109,194 shares of the company’s stock, valued at $22,756,029.60. This trade represents a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Joel Ackerman sold 51,471 shares of the stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the transaction, the chief financial officer directly owned 132,434 shares in the company, valued at approximately $25,440,571.40. This represents a 27.99% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 1.50% of the company’s stock.

Analyst Upgrades and Downgrades

DVA has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft upgraded shares of DaVita from a “hold” rating to a “buy” rating and upped their target price for the stock from $126.00 to $220.00 in a research report on Wednesday, May 6th. Zacks Research upgraded shares of DaVita from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Wall Street Zen upgraded shares of DaVita from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. TD Cowen upped their target price on shares of DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a research report on Monday, May 11th. Finally, UBS Group upped their target price on shares of DaVita from $190.00 to $235.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, DaVita currently has an average rating of “Hold” and a consensus price target of $199.17.

DaVita Stock Performance

Shares of DVA opened at $210.76 on Thursday. The company has a market capitalization of $13.53 billion, a price-to-earnings ratio of 19.55, a PEG ratio of 0.69 and a beta of 0.91. The company’s 50 day simple moving average is $179.88 and its 200 day simple moving average is $148.16. DaVita Inc. has a 1 year low of $101.00 and a 1 year high of $213.44.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.33 by $0.54. The company had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. DaVita’s revenue was up 6.0% on a year-over-year basis. During the same quarter last year, the firm posted $2.00 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities analysts expect that DaVita Inc. will post 15.07 EPS for the current fiscal year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.